共 47 条
PU.1 Regulates Positive Regulatory Domain I-Binding Factor 1/Blimp-1 Transcription in Lymphoma Cells
被引:16
作者:
Desai, Shruti
[1
,4
]
Bolick, Sophia C. E.
[1
,3
]
Maurin, Michelle
[1
]
Wright, Kenneth L.
[1
,2
,3
,4
]
机构:
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Oncol Sci, Tampa, FL 33612 USA
[3] Univ S Florida, Dept Mol Med, Tampa, FL 33612 USA
[4] Univ S Florida, Canc Biol PhD Program, Tampa, FL 33612 USA
基金:
美国国家卫生研究院;
关键词:
RNA-POLYMERASE-II;
MESSENGER-RNA;
TRANSACTIVATOR EXPRESSION;
BLIMP-1;
EXPRESSION;
B-CELLS;
C-MYC;
DIFFERENTIATION;
REPRESSION;
APOPTOSIS;
GENE;
D O I:
10.4049/jimmunol.0901120
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The human positive regulatory domain I-binding factor 1 (PRDI-BF1) and its murine homolog Blimp-1 promote differentiation of mature B cells into Ab-secreting plasma cells. In contrast, ectopic expression of PRDI-BF1 in lymphoma cells can lead to inhibition of proliferation or apoptosis. However, little is currently known about the regulation of PRDM1, the gene encoding PRDI-BF1. This report establishes that in lymphoma cells stimulation through the BCR rapidly induces endogenous PRDM1 at the level of transcription with minor changes in mRNA stability. The induced PRDM1-encoded protein localizes to its target genes in vivo and suppresses their expression. In vivo genomic footprinting of the PRDM1 promoter in unstimulated lymphoma and myeloma cells reveals multiple common in vivo occupied elements throughout the promoter. Further functional and structural analysis of the promoter reveals that the promoter is preloaded and poised for activation in the B cell lines. The transcription factor PU.1 is shown to be required for the BCR-induced expression of PRDM1 in lymphoma cells and in PU.1-positive myeloma cells. Activation of PRDM1 is associated with loss of the corepressor transducin-like enhancer of split 4 from the PU.1 complex. These findings indicate that PRDM1 is poised for activation in lymphoma cells and therefore may be a potential therapeutic target to inhibit lymphoma cell proliferation and survival. The Journal of Immunology, 2009, 183: 5778-5787.
引用
收藏
页码:5778 / 5787
页数:10
相关论文